Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2)
This study has been completed.
Sponsor:
Bayer
Collaborator:
Regeneron Pharmaceuticals
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT00637377
First received: March 12, 2008
Last updated: March 12, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.
| Condition | Intervention | Phase |
|---|---|---|
|
Macular Degeneration |
Drug: Ranibizumab Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD) |
Resource links provided by NLM:
Genetics Home Reference related topics:
age-related macular degeneration
tumor necrosis factor receptor-associated periodic syndrome
X-linked juvenile retinoschisis
U.S. FDA Resources
Further study details as provided by Bayer:
Primary Outcome Measures:
- Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) [ Time Frame: At week 52 ] [ Designated as safety issue: No ]
Maintenance of vision was defined as a loss of < 15 letters in the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score (defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
Nominator = (Number of participants who maintained vision * 100); Denominator = Number of participants analyzed.
Secondary Outcome Measures:
- Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 - LOCF [ Time Frame: Baseline and at week 52 ] [ Designated as safety issue: No ]Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
- Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF [ Time Frame: At week 52 ] [ Designated as safety issue: No ]
Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
Nominator = (Number of participants who maintained vision * 100); Denominator = Number of participants analyzed.
- Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF [ Time Frame: Baseline and at week 52 ] [ Designated as safety issue: No ]The possible range of the NEI VFQ-25 total score is between 0 (worst possible) and 100 (best possible).
- Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 - LOCF [ Time Frame: Baseline and at week 52 ] [ Designated as safety issue: No ]CNV area values measured in square millimeters; lower values represent better outcomes.
| Enrollment: | 1240 |
| Study Start Date: | April 2008 |
| Study Completion Date: | August 2011 |
| Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Ranibizumab 0.5mg Q4
Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
|
Drug: Ranibizumab
Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
|
|
Experimental: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4
Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
|
Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
|
|
Experimental: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4
Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
|
Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
|
|
Experimental: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8
Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
|
Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
|
Detailed Description:
Data of this trial ("VIEW 2") was pooled with data of a sister trial ("VIEW 1", NCT00509795), and an integrated analyses of the combined data was performed.
Eligibility| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Signed informed consent.
- Men and women >/=50 years of age.
- Active primary or recurrent subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by Fluorescein angiography (FA) in the study eye.
- ETDRS Best-Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters.
- Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.
- Able to read, (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) understand and willing to sign the informed consent form.
Exclusion Criteria:
- Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD, except dietary supplements or vitamins.
- Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye.
- Any prior treatment with anti-VEGF agents in the study eye.
- Total lesion size >12 disc areas (30.5 mm, including blood, scars and neovascularization) as assessed by FA in the study eye.
- Subretinal hemorrhages that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye (if the blood is under the fovea, then the fovea must be surrounded by 270 degrees by visible CNV).
- Scar or fibrosis making up >50% of the total lesion in the study eye.
- Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
- Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.
- History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.
- Presence of other causes of CNV in the study eye.
- Prior vitrectomy in the study eye.
- History of retinal detachment or treatment or surgery for retinal detachment in the study eye.
- Any history of macular hole of stage 2 and above in the study eye.
- Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of Day 1, as long as it is unlikely to interfere with the injection.
- History or clinical evidence of diabetic retinopathy, diabetic macular edema or any retinal vascular disease other than AMD in either eye.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00637377
Hide Study Locations
Hide Study LocationsLocations
| Argentina | |
| Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina, C1181ACH | |
| Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina, C1015ABO | |
| Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina, C1023AAQ | |
| Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina, C1122AAI | |
| Rosario, Santa Fe, Argentina, S2000ANJ | |
| Córdoba, Argentina, X5000IIT | |
| Australia, New South Wales | |
| Chatswood, New South Wales, Australia, 2067 | |
| Sydney, New South Wales, Australia, 2000 | |
| Westmead, New South Wales, Australia, 2145 | |
| Australia, Victoria | |
| East Melbourne, Victoria, Australia, 3002 | |
| Parkville, Victoria, Australia, 3050 | |
| Australia, Western Australia | |
| Nedlands, Western Australia, Australia, 6009 | |
| Australia | |
| Parramatta, Australia, 2150 | |
| Austria | |
| Innsbruck, Austria, 6020 | |
| Linz, Austria, 4021 | |
| Wien, Austria, 1090 | |
| Belgium | |
| Liege, Belgium, 4000 | |
| Brazil | |
| Ribeirão Preto, Sao Paulo, Brazil, 14048-900 | |
| São Paulo, Sao Paulo, Brazil, 05651-901 | |
| Minas Gerais, Brazil, 30150-270 | |
| Sao Paulo, Brazil, 04023-062 | |
| Colombia | |
| Medellín, Antioquia, Colombia | |
| Cali, Cauca, Colombia | |
| Bogota, Distrito Capital de Bogotá, Colombia | |
| Czech Republic | |
| Brno, Czech Republic, 63400 | |
| Olomouc, Czech Republic, 77520 | |
| Praha 10, Czech Republic, 10034 | |
| Praha 4, Czech Republic, 14000 | |
| Usti nad Labem, Czech Republic, 401 13 | |
| France | |
| Paris, Cedex 12, France, 75557 | |
| Nantes, Cedex 1, France, 44093 | |
| Besancon, France, 25030 | |
| Bordeaux, France, 33000 | |
| Dijon, France, 21079 | |
| Lyon, France, 69006 | |
| Lyon, France, 69003 | |
| Marseille, France, 13008 | |
| Paris, France, 75010 | |
| Paris, France, 75015 | |
| Germany | |
| Freiburg, Baden-Württemberg, Germany, 79106 | |
| Heidelberg, Baden-Württemberg, Germany, 69120 | |
| Tübingen, Baden-Württemberg, Germany, 72076 | |
| München, Bayern, Germany, 81675 | |
| Regensburg, Bayern, Germany, 93053 | |
| Darmstadt, Hessen, Germany, 64297 | |
| Aachen, Nordrhein-Westfalen, Germany, 52074 | |
| Bonn, Nordrhein-Westfalen, Germany, 53105 | |
| Essen, Nordrhein-Westfalen, Germany, 45122 | |
| Köln, Nordrhein-Westfalen, Germany, 50924 | |
| Münster, Nordrhein-Westfalen, Germany, 48145 | |
| Ludwigshafen, Rheinland-Pfalz, Germany, 67063 | |
| Mainz, Rheinland-Pfalz, Germany, 55131 | |
| Homburg, Saarland, Germany, 66421 | |
| Dresden, Sachsen, Germany, 01307 | |
| Dresden, Sachsen, Germany, 06067 | |
| Leipzig, Sachsen, Germany, 04103 | |
| Kiel, Schleswig-Holstein, Germany, 24105 | |
| Lübeck, Schleswig-Holstein, Germany, 23538 | |
| Berlin, Germany, 12200 | |
| Hamburg, Germany, 20251 | |
| Hungary | |
| Budapest, Hungary, 1133 | |
| Budapest, Hungary, 1106 | |
| Budapest, Hungary, 1083 | |
| Veszprem, Hungary, 8200 | |
| India | |
| Ahemedabad - 4, Gujrat, India, 380009 | |
| Wadala, Mumbai, Maharashtra, India, 400031 | |
| Chennai, Tamil Nadu, India, 600 006 | |
| Coimbatore, Tamil Nadu, India, 641014 | |
| Madurai, Tamil Nadu, India, 625 020 | |
| Pondicherry, Tamil Nadu, India, 600007 | |
| Bangalore, India, 560010 | |
| Chandigarh, India, 160012 | |
| Hyderabad, India, 500 034 | |
| Kerala, India, 683572 | |
| Kolkata, India, 700073 | |
| Mumbai, India, 400 050 | |
| New Delhi, India, 110002 | |
| New Delhi, India, 110029 | |
| Orissa, India, 751 024 | |
| Israel | |
| Afula, Israel | |
| Beer Sheva, Israel | |
| Haifa, Israel, 34362 | |
| Jerusalem, Israel, 91120 | |
| Kfar Saba, Israel | |
| Petach Tikva, Israel, 49100 | |
| Rehovot, Israel, 76100 | |
| Tel Aviv, Israel, 64239 | |
| Tel Hashomer, Israel | |
| Zrifin, Israel, 70300 | |
| Italy | |
| Ancona, Italy, 60126 | |
| Bari, Italy, 70124 | |
| Catania, Italy, 95123 | |
| Genova, Italy, 16132 | |
| Milano, Italy, 20157 | |
| Milano, Italy, 20122 | |
| Milano, Italy, 20132 | |
| Padova, Italy, 35128 | |
| Roma, Italy, 00168 | |
| Roma, Italy, 00198 | |
| Roma, Italy, 00133 | |
| Torino, Italy, 10122 | |
| Udine, Italy, 33100 | |
| Varese, Italy, 21100 | |
| Verona, Italy, 37121 | |
| Japan | |
| Nagoya, Aichi, Japan, 466-8560 | |
| Nagoya, Aichi, Japan, 467-8602 | |
| Urayasu, Chiba, Japan, 279-0021 | |
| Maebashi, Gunma, Japan, 371-8511 | |
| Sapporo, Hokkaido, Japan, 060-8604 | |
| Kita, Kagawa, Japan, 761-0793 | |
| Hirakata, Osaka, Japan, 573-1191 | |
| Suita, Osaka, Japan, 565-0871 | |
| Otsu, Shiga, Japan, 520-2192 | |
| Chiyoda-ku, Tokyo, Japan, 101-8309 | |
| Shinjuku-ku, Tokyo, Japan, 160-8582 | |
| Fukuoka, Japan, 812-8582 | |
| Fukushima, Japan, 960-1295 | |
| Kagoshima, Japan, 890-8520 | |
| Kyoto, Japan, 606-8507 | |
| Korea, Republic of | |
| Seongnam, Gyeonggido, Korea, Republic of, 463 707 | |
| Incheon, Korea, Republic of, 405-760 | |
| Seoul, Korea, Republic of, 138-736 | |
| Seoul, Korea, Republic of, 110 744 | |
| Seoul, Korea, Republic of, 152-703 | |
| Seoul, Korea, Republic of, 137 701 | |
| Latvia | |
| Riga, Latvia, 1050 | |
| Riga, Latvia, 1009 | |
| Riga, Latvia, 1002 | |
| Mexico | |
| Mexico City, Distrito Federal, Mexico, 06800 | |
| Zapopan, Jalisco, Mexico, 45060 | |
| Metepec, México, Mexico, 52140 | |
| Monterrey, Nuevo Leon, Mexico, 64060 | |
| Monterrey, Nuevo Leon, Mexico, 64480 | |
| Chihuahua, Mexico, 31238 | |
| Mexico City, Mexico, 06030 | |
| México D.F., Mexico, 04030 | |
| Netherlands | |
| Leiden, ZA, Netherlands, 2333 | |
| Amsterdam, Netherlands, 1100 DD | |
| Groningen, Netherlands, 9713 GZ | |
| Nijmegen, Netherlands, 6525 EX | |
| Rotterdam, Netherlands, 3000 CA | |
| Poland | |
| Bydgoszcz, Poland, 85-631 | |
| Gdansk, Poland, 80-952 | |
| Katowice, Poland, 40-760 | |
| Poznan, Poland, 61-848 | |
| Warszaa, Poland, 02-005 | |
| Warszawa, Poland, 00-416 | |
| Wroclaw, Poland, 50-368 | |
| Portugal | |
| Coimbra, Portugal, 3000-548 | |
| Porto, Portugal, 4200-319 | |
| Singapore | |
| Singapore, Singapore, 159964 | |
| Singapore, Singapore, 308433 | |
| Singapore, Singapore, 119074 | |
| Singapore, Singapore, 168751 | |
| Slovakia | |
| Banska Bystrica, Slovakia, 97517 | |
| Bratislava, Slovakia, 81369 | |
| Spain | |
| Santiago de Compostela, A Coruña, Spain, 15705 | |
| Oviedo, Asturias, Spain, 33012 | |
| Pamplona, Navarra, Spain, 31008 | |
| Alicante, Spain, 03016 | |
| Barcelona, Spain, 08017 | |
| Barcelona, Spain, 08036 | |
| Barcelona, Spain, 08035 | |
| Barcelona, Spain, 08022 | |
| Madrid, Spain, 28002 | |
| Madrid, Spain, 28046 | |
| Malaga, Spain, 29010 | |
| Sevilla, Spain, 41013 | |
| Sevilla, Spain, 41009 | |
| Valencia, Spain, 46015 | |
| Valencia, Spain, 46014 | |
| Valladolid, Spain, 47005 | |
| Sweden | |
| Linköping, Sweden, 58185 | |
| Stockholm, Sweden, 11282 | |
| Örebro, Sweden, 70185 | |
| Switzerland | |
| Basel, Switzerland, 4031 | |
| Bern, Switzerland, 3010 | |
| Genève, Switzerland, 1211 | |
| Zürich, Switzerland, 8091 | |
| United Kingdom | |
| Southampton, Hampshire, United Kingdom, SO16 6YD | |
| Camberley, Surrey, United Kingdom, GU16 5UJ | |
| Aberdeen, United Kingdom, AB25 2ZN | |
| Belfast, United Kingdom, BT12 6BA | |
| Birmingham, United Kingdom, B4 7ET | |
| Liverpool, United Kingdom, L7 8XP | |
| London, United Kingdom, SE5 9RS | |
| London, United Kingdom, NW1 5QH | |
| Plymouth, United Kingdom, PL4 6PL | |
| Torquay, United Kingdom, TQ2 7AA | |
Sponsors and Collaborators
Bayer
Regeneron Pharmaceuticals
Investigators
| Study Director: | Bayer Study Director | Bayer |
More Information
Additional Information:
Publications:
| Responsible Party: | Therapeutic Area Head, Bayer Healthcare AG |
| ClinicalTrials.gov Identifier: | NCT00637377 History of Changes |
| Other Study ID Numbers: | 91689, 2007-000583-25 |
| Study First Received: | March 12, 2008 |
| Results First Received: | December 16, 2011 |
| Last Updated: | March 12, 2013 |
| Health Authority: | Switzerland: Swiss Medic Argentina: Ministry of Health Australia: Department of Health and Ageing Therapeutic Goods Administration Austria: Federal Office for Safety in Health Care Belgium: Federal Agency for Medicinal Products and Health Products Brazil: ANVISA Agencia Nacional de Vigilancia Sanitaria Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos Czech Republic: State Institute for Drug Control France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Germany: Federal Institute for Drugs and Medical Devices Hungary: National Institute of Pharmacy India: Drugs Controller General of India Israel: Ministry of Health Italy: Ethics Committee Japan: Pharmaceuticals and Medical Devices Agency South Korea: Korea Food and Drug Administration (KFDA) Latvia: State Agency of Medicines Mexico: Federal Commission for Sanitary Risks Protection Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Portugal: INFARMED National Authority of Medicines and Health Products Singapore: Health Sciences Authority Slovakia: State Institute for Drug Control Spain: Ministry of Health and Consumption Sweden: Medical Products Agency United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Keywords provided by Bayer:
|
Eye diseases Vision Impairment and Blindness Eyes and Vision |
Seniors Neovascular Age-Related Macular Degeneration (AMD) Retinal Disease |
Additional relevant MeSH terms:
|
Macular Degeneration Wet Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases |
Endothelial Growth Factors Growth Substances Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 22, 2013